Quick Answer
LIGAND PHARMACEUTICALS INC reported Net Income Loss of $124.45 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +3,186.6% in Net Income Loss from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Net Income Loss has grown by 6,488.8%.
- Historical annual values: Fiscal year 2025: $124.45 million | Fiscal year 2024: -$4.03 million | Fiscal year 2023: $52.15 million | Fiscal year 2022: -$33.36 million | Fiscal year 2021: $57.14 million | Fiscal year 2020: -$2.99 million | Fiscal year 2019: $629.30 million | Fiscal year 2018: $143.32 million | Fiscal year 2017: $12.56 million | Fiscal year 2016: -$1.64 million | Fiscal year 2015: $229.82 million | Fiscal year 2014: $12.02 million | Fiscal year 2013: $11.42 million | Fiscal year 2012: -$527.0 thousand | Fiscal year 2011: $9.72 million | Fiscal year 2010: -$10.37 million | Fiscal year 2009: -$1.95 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: